Seeman P, Guan H C, Van Tol H H, Niznik H B
Department of Pharmacology, University of Toronto, Ontario, Canada.
Synapse. 1993 Aug;14(4):247-53. doi: 10.1002/syn.890140402.
The purpose of this study was to determine whether dopamine D4 receptors could be detected in the human brain striatum by means of an indirect ligand-binding method, because no dopamine D4 receptor-selective ligand presently exists. The antipsychotic clozapine is more selective for the dopamine D4 receptor than for other dopamine receptors. Although most antipsychotic drugs act in the striatum to elicit Parkinson-like side-effects, clozapine is atypical in that it does not produce Parkinsonism. To understand this atypical action of clozapine, it would be helpful to know whether the presumed target for clozapine, the dopamine D4 receptor, is or is not present in the human striatum. We measured dopamine D4 receptors indirectly, using [3H]emonapride and [3H]raclopride. Emonapride has a high affinity (K = 90 pM) for the dopamine D4 receptor, while raclopride has a very low affinity for this receptor (K = 240 nM); thus, any difference in the densities of these two [3H]ligands (in the absence of dopamine) could be attributed to the presence of dopamine D4 receptors. Since the binding of [3H]raclopride is sensitive to endogenous dopamine, we used Parkinson-diseased tissue which has little dopamine. We found that the densities of the two ligands were identical in Parkinson striata, indicating a low density (< 1 pmol/g) for dopamine D4 receptors in the human striatum. This low or undetectable density of dopamine D4 receptors in the striatum is consistent with other data indicating that clozapine does not have its major action in the human striatum.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究的目的是通过间接配体结合方法确定人类脑纹状体中是否能检测到多巴胺D4受体,因为目前尚无多巴胺D4受体选择性配体。抗精神病药物氯氮平对多巴胺D4受体的选择性高于其他多巴胺受体。尽管大多数抗精神病药物在纹状体中起作用会引发帕金森样副作用,但氯氮平却不典型,它不会产生帕金森症。为了解氯氮平的这种非典型作用,了解其假定靶点多巴胺D4受体在人类纹状体中是否存在将很有帮助。我们使用[3H]依莫必利和[3H]雷氯必利间接测量多巴胺D4受体。依莫必利对多巴胺D4受体具有高亲和力(K = 90 pM),而雷氯必利对该受体的亲和力非常低(K = 240 nM);因此,这两种[3H]配体(在无多巴胺情况下)密度的任何差异都可归因于多巴胺D4受体的存在。由于[3H]雷氯必利的结合对内源性多巴胺敏感,我们使用多巴胺含量很少的帕金森病组织。我们发现帕金森病纹状体中两种配体的密度相同,表明人类纹状体中多巴胺D4受体密度较低(<1 pmol/g)。纹状体中多巴胺D4受体这种低密度或无法检测到的密度与其他数据一致,这些数据表明氯氮平在人类纹状体中并非主要起作用。(摘要截短至250字)